Diaxonhit (ALEHT) Increases 0.1% on Jun 19

June 19, 2018 - By Winifred Garcia

Shares of Diaxonhit (EPA:ALEHT) last traded at 4.925, representing a move of 0.1%, or 0.005 per share, on volume of 191 shares. After opening the trading day at 4.925, shares of Diaxonhit traded in a close range. Diaxonhit currently has a total float of 9.78M shares and on average sees 12,221 shares exchange hands each day. The stock now has a 52-week low of 4.14 and high of 7.

French Stock Market: A European Prowess

France is not just all about the unparalleled gastronomic experience nor the beautiful destinations. It is also acknowledged for being one of Europe’s pride on the economic front. It is also a special market place for Diaxonhit. With a thriving corporate sector, France surely has an interesting economy as well.

France’s Equity Market

Euronext Paris, which was formerly known as Paris Bourse, is the main stock exchange in France. It is part of Euronext, a pan-European stock exchange across five European cities including Paris, London, Lisbon, Brussels, and Amsterdam.

Euronext was established on September 22, 2000, creating the first pan-European stock exchange from the merger of the Amsterdam Stock Exchange, the Brussels Stock Exchange, and the Paris Bourse in an effort to leverage the European Union (EU) economy. In 2002, the Bolsa de Valores de Lisboa was integrated into the union, further strengthening one of Europe’s biggest stock exchanges.

Developing very quickly it helped many companies like Diaxonhit to find their investors. As of the first quarter of 2014, Euronext has a total market capitalization of €1.60 trillion with over 1,000 companies listed on it.

The leading indices on Euronext include PSI 20, Next 150, Euronext 100, CAC 40, BEL 20, AScX, AMX, and AEX.

CAC 40 is the index measuring the 40 most valuable companies listed on Euronext Paris. Unlike the leading index in the US, the Dow Jones Industrial Average— a price-weighted index, CAC 40 is a free-float modified capitalization-weighted index since December 1, 2003. Prior to this, its components are measured based on total market capitalization.

CAC 40 derives its name from an old automation system of Euronext Paris. Its base value of 1,000 has been set on December 31, 1987.

CAC 40 had recorded its all-time high 16 years ago, closing at 6,922.33 on September 4, 2000. It had an intraday high of 6,944.77 during the said session. On the other hand, its all-time low of 893.22 was last seen in January 1988. At present, CAC 40 is trading at around 4,000. And Diaxonhit is the part of this trading.

The components of CAC 40 are reviewed and determined every quarter by the Index Steering Committee. The reviews happen every third Friday of March, June, September, and December. Companies listed on Euronext Paris are ranked based on free-float market valuation and share turnover in the 12 months prior. Their weights are limited to 15% during review to prevent the occurrence of index heavyweight. From the top 100 companies, 40 companies will be picked to compose CAC 40.

Trading in France

France has one of the longest regular trading sessions in the world. Trading on Euronext Paris begins at 6:01 a.m. and ends at 7:59 p.m. The movement is in 0.50 increments. Among most brokers, the margin requirement is 2%. Meanwhile, the minimum trade size requirement is an index. Euro is the main currency on Euronext Paris.

France is one of the richest economies in Europe, which is why betting on its growth prospects is an ideal move for investors. CAC 40 lives up to global stock exchange standards that can truly reward meaningful investments. Some of investments go to the Diaxonhit directly.

Diaxonhit discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company has market cap of 48.15 million EUR. It offers Tetanus Quick Stick, a test that is used in emergency clinics for the determination of the tetanus vaccination status of a patient. It currently has negative earnings. The company's in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; and Dx15, a test for the diagnosis of thyroid cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: